ArticleJournal of Crohn's & colitis2026
Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsIntestinal barrier impairment (BI) is a hallmark of inflammatory bowel disease (IBD), driving immune activation, neutrophil-mediated injury, and chronic mucosal damage. While endoscopy and molecular profiling provide insight into epithelial and vascular assessment, the combined prognostic role of histology and BI remains insufficiently defined. This study aimed to determine the association between histology-derived signatures and BI, and identify outcome predictors by integrating histologic, advanced imaging, and molecular data.
methodsIBD patients underwent in vivo epithelial and vascular barrier assessment using probe-based confocal laser endomicroscopy and endocytoscopy. Biopsies were collected for histologic and protein expression analysis. Epithelial (ZO-1, Claudin-2, E-cadherin) and vascular-barrier proteins (CD31, PV-1) were analyzed using confocal microscopy and automated quantification with QuPath. Correlation among histology, advanced imaging, and protein expression was assessed, together with the ability to predict outcome at 12 months of follow-up.
resultsEighty-eight IBD patients (52 Crohn's disease [CD] and 36 ulcerative colitis [UC]) were included. BI was identified in 35/52 (67%) CD and 28/36 (78%) UC patients. Epithelial and lamina propria neutrophils correlated strongly with epithelial BI (r = 0.6). Chronic inflammatory infiltrate correlated significantly with vascular BI (r = 0.5) and PV-1 expression (r = 0.3) in CD. Finally, CD patients with both barrier alterations (advanced imaging + PV-1) and inflammatory infiltrate showed a higher rate of adverse outcomes than those with single alterations.
conclusionHistologic signatures correlate significantly with BI in IBD. Multimodal evaluation combining histology, advanced imaging, and molecular profiling improves outcome prediction beyond single-modality assessment and may identify patients with subclinical disease persistence, supporting accurate risk stratification and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.